ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 5, 2017
Competitive Pressures Not Going Away for Teva
Image Source: Mylan. The end of the patent life of a lucrative product can often lead to significant legal strife as aspiring biosimilar equivalents jockey for exclusivity. We have found the recent aggressive move by Mylan noteworthy in our ongoing coverage of Teva’s recent struggles. On a separate but related note, the settlement between Amgen and Abbvie underscores the volatile nature of maneuvers conducted in order to extend the patent life of a highly successful product.
Oct 5, 2017
The Legal Battle Between Regeneron and Amgen Heats Up
Image Source: Regeneron. The legal battle between two of the titans of the biotech world heated up further with a recent ruling overturning the injunction of a critical asset. We are updating our thesis in light of current events.
Oct 4, 2017
Housing Market Very Strong But To “Face Two Contradicting Challenges”
Image Shown: The iShares US Home Construction ETF (ITB) has advanced ~ 24% year-to-date, according to data from YahooFinance. “Housing indicators may be leveling off,” per S&P Corelogic, and the threat of rising interest rates looms (as it has for years), but we like the fundamental strength that we’re seeing from the homebuilders of late, which has translated into strong equity performance.
Oct 3, 2017
Intel’s Stock Is Marching Ever Higher
Image Shown: Intel's shares have been catching a bid lately. Shares of newsletter portfolio idea Intel are cheap by our estimates, and the company sports a nice dividend yield to boot. Does it have further upside potential?
Oct 2, 2017
General Motors Is Off to the Races!
Image Shown: GM's shares are breaking out. GM's stock has been out of favor for years, but with an attractive price-to-earnings ratio and healthy dividend yield, is the market finally coming around to the company’s tremendous potential?
Oct 2, 2017
Verint Systems: An Overlooked Idea on Cybersecurity
Image Source: Verint. The Best Ideas Newsletter idea is trying to break through the mid-$40s level, which has been illusive since late 2015.
Oct 1, 2017
Dividend Increases for the Week Ending September 29
Let's take a look at companies raising/lowering their dividends this week.
Sep 30, 2017
Will Texas Tea Hit $75 Per Barrel By Year’s End?
Image Shown: The performance of the VanEck Vectors Oil Refiners ETF (CRAK) since its launch in August 2015.We’ve witnessed our fair share of fits and starts from energy resource prices during the past few years, but could the global crude markets finally be rebalancing? Let’s talk about our thoughts on whether the outlook for energy resource pricing is improving in a sustainable way.
Sep 30, 2017
Amazon Casts a Large Shadow Over the Pharmacy Industry
Image Source:  Mike Mozart. It is our belief the food retailing industry is in the midst of widespread disruption with Amazon’s attempt to break into the supermarket game with its audacious purchase of Whole Foods. The Whole Foods acquisition is not likely to be an isolated one-off event; instead, it may be a harbinger of Amazon’s ambition to break into new markets, thus expanding its overall percentage of retail sales. We update our views on Amazon and how the company may eventually impact newsletter portfolio holding CVS Health.
Sep 24, 2017
Dividend Increases/Decreases for the Week Ending September 22
Let's take a look at companies raising/lowering their dividends this week.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.